Clinical Trials

Fast Facts

Our clinical trials portfolio includes:

  • More than 40 research studies
  • More than 10 Pediatric-focused studies
  • Five phase-1 Trials
  • First-In-Human treatments
  • Investigational New Drugs developed at UF

Featured Trial

PNOC 020

A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).

Subject inclusion criteria:

  • Age: 21 Years and older (Adult, Older Adult)
  • Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
  • The tumor must have a supratentorial component.
  • Bone Marrow, Renal and Hepatic tests

See full inclusion criteria and learn more about the PNOC 020 Clinical Trial

Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.

 


Browse or search current neurosurgery clinical trials

ATTAC-II

A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma.

ACTION

Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas

BRAVO

BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide

TORCH

Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH) Read more on UFHealth.org

RENEW

Pilot Study of Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the treatment of Newly Diagnosed Glioblastoma Patients

PEACH

Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG).